GSH-resistant and highly cytoselective ruthenium(<scp>ii</scp>)-<i>p</i>-cymene-(imidazo[4,5-<i>f</i>][1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents

Kar, Binoy; Das, Utpal; De, Sourav; Pete, Sudhindra; S, Ajay Sharma; Roy, Nilmadhab; Kumar, Sanjeev; Panda, Debashis; Paira, Priyankar

doi:10.1039/d1dt01604k

Cited by 19 publications

(22 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,37,38 The incorporation of a hydrophobic Ru (II)-p-cymene moiety increases drug transportation towards a particular organelle and the presence of labile -Cl is involved in DNA covalent interaction and other biomolecular interaction. 39,40 The purpose of the current work is not only to develop a new synthetic route for the synthesis of (η 6 -pcymene)Ru II Cl(K 2 -N,N-dipyrido[3,2-a:2′,3′-c]phenazine complexes using a green protocol, but also to further explore their extensive luminescence properties and ROS generating ability in selective phototoxicity towards cancerous cells.…”

Section: Introductionmentioning

confidence: 99%

One pot three component synthesis of DNA targeting phototoxic Ru(ii)-p-cymene dipyrido[3,2-a:2′,3′-c]phenazine analogues

Kar

Paira

2022

Dalton Trans.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

One pot three component synthesis of DNA targeting phototoxic Ru(ii)-p-cymene dipyrido[3,2-a:2′,3′-c]phenazine analogues

Kar

Paira

2022

Dalton Trans.

View full text Add to dashboard Cite

show abstract

“…According to the previous work, 20 mg of ligand L (0.049 mmol, 1 equiv) and 14 mg of [Ru 2 II (η6- p -cym) 2 (Cl) 4 ] (0.023 mmol, 0.5 equiv.) were used to synthesis RuL .…”

Section: Methodsmentioning

confidence: 99%

Luminescent 11-{Naphthalen-1-yl}dipyrido[3,2-a:2′,3′-c]phenazine-Based Ru(II)/Ir(III)/Re(I) Complexes for HCT-116 Colorectal Cancer Stem Cell Therapy

Das

Shanavas

Nagendra

et al. 2023

ACS Appl. Bio Mater.

Self Cite

View full text Add to dashboard Cite

Due to a number of unpleasant considerations, marketed drugs have steadily lost their importance in the treatment of cancer. In order to find a viable cancer cell diagnostic agent, we therefore focused on metal complexes that displayed target adequacy, permeability to cancer cells, high standard water solubility, cytoselectivity, and luminescent behavior. In this aspect, luminescent 11-{naphthalen-1-yl} dipyrido [3,2-a:2′,3′-c] phenazine based Ru(II)/Ir(III)/Re(I) complexes have been prepared for HCT-116 colorectal cancer stem cell therapy. Our study successfully established the possible cytotoxicity of IrL complex at different doses on HCT-116 colorectal cancer stem cells (CRCSCs). Additionally, an immunochemistry analysis of the complex IrL showed that the molecule was subcellularly localized in the nucleus and other regions of the cytoplasm, where it caused nuclear DNA damage and mitochondrial dysfunction. The level of BAX and Bcl-2 was further quantified by qRT-PCR. The expression of proapoptotic BAX showed increased expression in the complex IrL-treated cell compared to the control, indicating the potential of complex IrL for apoptotic induction. Upon further validation, complex IrL was developed as an inhibitor of autophagy for the eradication of cancer stem cells.

show abstract

“…A series of Ru(II)-p-cymene-imidazophenanthroline complexes [ 62 ] were synthesized and tested against the HeLa and CaCo-2 cancer cell lines and normal HEK-293 cells. CT-DNA and bovine serum albumin (BSA) binding was noted.…”

Section: Novel Metal Complexes In Cancer Therapymentioning

confidence: 99%

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Todorov

Kostova

2023

Molecules

View full text Add to dashboard Cite

Since the accidental discovery of the anticancer properties of cisplatin more than half a century ago, significant efforts by the broad scientific community have been and are currently being invested into the search for metal complexes with antitumor activity. Coordination compounds of transition metals such as platinum (Pt), ruthenium (Ru) and gold (Au) have proven their effectiveness as diagnostic and/or antiproliferative agents. In recent years, experimental work on the potential applications of elements including lanthanum (La) and the post-transition metal gallium (Ga) in the field of oncology has been gaining traction. The authors of the present review article aim to help the reader “catch up” with some of the latest developments in the vast subject of coordination compounds in oncology. Herewith is offered a review of the published scientific literature on anticancer coordination compounds of Pt, Ru, Au, Ga and La that has been released over the past three years with the hope readers find the following article informative and helpful.

show abstract

GSH-resistant and highly cytoselective ruthenium(ii)-p-cymene-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol complexes as potential anticancer agents

Abstract: To avoid several side effect of platinum based popular anticancer drugs, tireless attempt of researchers afforded them to contemplate the way of designing the appropriate GSH resistant Ru(II)-arene complexes. In...

Cited by 19 publications

References 56 publications

One pot three component synthesis of DNA targeting phototoxic Ru(ii)-p-cymene dipyrido[3,2-a:2′,3′-c]phenazine analogues

One pot three component synthesis of DNA targeting phototoxic Ru(ii)-p-cymene dipyrido[3,2-a:2′,3′-c]phenazine analogues

Luminescent 11-{Naphthalen-1-yl}dipyrido[3,2-a:2′,3′-c]phenazine-Based Ru(II)/Ir(III)/Re(I) Complexes for HCT-116 Colorectal Cancer Stem Cell Therapy

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Contact Info

Product

Resources

About